Clinical Trials
23 trialsNCT04895709 2026-06-04
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06171789 2026-06-01
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT04152499 2026-05-11
MK-2870-001
Klus Pharma Inc.
Phase 1/2 Active not recruiting
NCT07287995 2026-04-23
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT06943521 2025-12-11
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Phase 1/2 Recruiting
NCT05706129 2025-10-20
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
Phase 1/2 Recruiting
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT03674567 2025-01-24
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
Phase 1/2 Completed
NCT05620134 2024-10-15
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Phase 1/2 Active not recruiting
NCT03665285 2024-03-08
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Completed
NCT03992131 2024-01-16
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
pharmaand GmbH
Phase 1/2 Terminated
NCT04639245 2023-08-03
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT05219578 2022-12-09
RTX-224 Monotherapy in Patients With Solid Tumors
Rubius Therapeutics
Phase 1/2 Terminated
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT05234606 2022-04-12
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Silverback Therapeutics
Phase 1/2 Withdrawn
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated